Abstract: Methods and compositions for treating or preventing cerebral stroke, cerebral infarction, cerebral edema, reperfusion injury and increased cerebral vascular permeability which employ an agent that prevents the binding of IL-8 to its receptor are disclosed.

Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Abstract: A therapeutic agent for treatment of acute lung injury, especially acute respiratory distress syndrome and adult respiratory distress syndrome, resulting from indirect causes, especially the sepsis syndrome, severe nonthoracic trauma, hypertransfusion during emergency resuscitation, and an artificial cardiopulmonary bypass surgery, and a therapeutic agent for hypoxemia in acute lung injury, said agents comprising anti-IL-8 antibody as an active ingredient.

Abstract: A human ADAMTS-1 protein, a gene encoding the same, a pharmaceutical composition containing the protein as an active ingredient, and a method for immunologically analyzing the human ADAMTS-1 protein are disclosed. The protein can decrease the number of leukocytes and platelets, and at the same time, increase the number of erythrocytes.

Abstract: The present invention discloses a reshaped human antibody against human IL-8 comprising:

Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Abstract: The present invention discloses a therapeutic agent for sepsis, and particularly septic shock, an agent for improving decreased arterial pressure of septic shock, and an agent for relieving increased respiration rate of septic shock, all containing for their active ingredient anti-IL-8 antibody.

Abstract: A therapeutic agent for rheumatoid arthritis comprising anti-IL-8 antibody as an active ingredient.

Abstract: A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.

Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Abstract: The present invention discloses a reshaped human antibody against human IL-8 comprising:(A) L chains each comprising:(1) a human L chain C region; and,(2) an L chain V region comprising a human Lchain FR, and an L chain CDR of mouse monoclonal antibody against human IL-8; and,(B) H chains each comprising:(1) a human H chain C region; and,(2) an H chain V region comprising a human Hchain FR, and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the majority of this reshaped human antibody originates in human antibody and the CDR has low antigenicity, the reshaped human antibody of the present invention has low antigenicity to humans, and can therefore be expected to be useful in medical treatment. The present invention further discloses polynucleotides which encode reshaped antibodies against IL-8, as well as host cells and methods to produce these antibodies.

Abstract: The present invention discloses an antiinflamatory agent or immunosuppressant that contains as its active ingredient a peptide that inhibits phosphorylation of I.kappa.B.alpha., an example of which is the peptide having the following amino acid sequence (SEQ ID NO: 1): Met-Leu-Pro-Glu-Ser-Glu-Asp-Glu-Glu-Ser-Tyr-Asp-Thr-Glu-Ser-Glu-Phe-Thr-Gl u-Phe-Thr-Glu-Asp-Glu-Leu.

Abstract: An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Abstract: A method for ameliorating at least one of the symptoms of nephritis is disclosed. Administration of antibodies or immunologically reactive fragments thereof which are immunoreactive with the IL-8 of the subject suppresses the elevated excretion of protein and infiltration of neutrophils associated with this condition.

Abstract: The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.

Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Abstract: A therapeutic agent for treating wounds having properties and actions different from those of growth factors and proteins inducing growth factors, which have strong therapeutic effect is disclosed. The therapeutic agent for treating wounds according to the present invention comprises monocyte chemotactic and activating factor or a variation thereof having a monocyte-attracting property or a derivative of said monocyte chemotactic and activating factor or said variation thereof.